Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07123467 · ClinicalTrials.gov registry record · Phase 3
Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder
A Phase 3 study of Anxiety Disorders and Generalized Anxiety Disorder (GAD), sponsored by Wayne State University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT07123467: Recruiting Phase 3 study of Anxiety Disorders and Generalized Anxiety Disorder (GAD), sponsored by Wayne State University.
NCT07123467 is a Phase 3 study of Anxiety Disorders and Generalized Anxiety Disorder (GAD) that is actively recruiting participants, run by Wayne State University. The registered enrollment target is 90 participants, below the 1,139-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07123467, a Phase 3 study of Anxiety Disorders and Generalized Anxiety Disorder (GAD), is actively recruiting participants, sponsored by Wayne State University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized, double-blind, placebo-controlled clinical trial investigates the use of Food and Drug Administration (FDA)-approved cannabidiol (EPIDIOLEX®) as an adjunct to cognitive behavioral therapy (CBT) in adults with generalized anxiety disorder (GAD). The study aims to evaluate whether cannabidiol-assisted CBT enhances emotion regulation via dorsomedial prefrontal cortex (dmPFC) activation and improves anxiety symptom outcomes compared to CBT with placebo.
Primary Outcome
Within-participant change in dorsomedial prefrontal cortex (dmPFC) activation will be calculated as post-treatment minus baseline values during an explicit emotion regulation task (Reappraise \> Maintain contrast). Measured using blood-oxygen-level-dependent (BOLD) signal from multi-echo functional magnetic resonance imaging (fMRI).
Conditions Studied
Interventions
- DRUG Low-Dose Cannabidiol
- DRUG Placebo Matched to Moderate-Dose Cannabidiol
- DRUG Moderate-Dose Cannabidiol
- DRUG Placebo Matched to Low-Dose Cannabidiol
Study Locations (1)
Michigan
- Wayne State University School of Medicine, Tolan Park Medical Building - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 3 |
What NCT07123467 shows while recruiting
NCT07123467 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 1,139-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Anxiety Disorders appearing as the primary indexed condition, and to 4 interventions - of which Low-Dose Cannabidiol is the first listed.
NCT07123467 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT07123467 about?
NCT07123467 is a clinical study titled "Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder". This randomized, double-blind, placebo-controlled clinical trial investigates the use of Food and Drug Administration (FDA)-approved cannabidiol (EPIDIOLEX®) as an adjunct to cognitive behavioral therapy (CBT) in adults with generalized anxiety disorder (GAD). The study aims to evaluate whether cann...
What is the current status of trial NCT07123467?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2025-11-03. Estimated completion is 2027-08-31.
What conditions does trial NCT07123467 study?
This clinical trial studies the following conditions: Anxiety Disorders, Generalized Anxiety Disorder (GAD).
What interventions are being tested in trial NCT07123467?
The interventions under investigation include: Low-Dose Cannabidiol (DRUG), Placebo Matched to Moderate-Dose Cannabidiol (DRUG), Moderate-Dose Cannabidiol (DRUG), Placebo Matched to Low-Dose Cannabidiol (DRUG).
Who is sponsoring clinical trial NCT07123467?
This trial is sponsored by Wayne State University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07123467 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07123467's enrollment target sits among peer trials
90 50th of 84 higher than 33 of 84 other Anxiety Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fluoxetine vs CBT in Childhood Anxiety Disorders
ACTIVE NOT RECRUITING · Phase 3
-
A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder
COMPLETED · Phase 3
-
Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS
COMPLETED · Phase 3
-
Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)
COMPLETED · Phase 3
-
Telephone-Based Care Management Program for Individuals With Anxiety Disorders
COMPLETED · Phase 3
-
School-based Treatment for Anxious Children
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI